Drug interactions
Concizumab + Factor viii
Severity: Major
Concizumab and Factor viii: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Concizumab reduces bleeding by inhibiting tissue factor pathway inhibitor, so added factor VIII at high or frequent doses can increase thrombotic risk. Thromboembolic events have been reported with concomitant breakthrough-bleed treatment.
What this interaction means in plain words
Concizumab and Factor viii can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Concizumab belongs to Miscellaneous; Factor viii belongs to Cardiovascular.
Why it happens
Additive procoagulant effects of TFPI inhibition and exogenous factor replacement.
What to do
Treat breakthrough bleeds with the lowest approved factor VIII dose that achieves hemostasis. Monitor for signs of thrombosis.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Concizumab and Factor viii, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Concizumab
- Concizumab + Factor ix Major
Other interactions of Factor viii
Frequently asked questions
Can I take Concizumab with Factor viii?
MediHelp rates the interaction as major. Concizumab and Factor viii can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Concizumab reduces bleeding by inhibiting tissue factor pathway inhibitor, so added factor VIII at high or frequent doses can increase thrombotic risk. Thromboembolic events have been reported with concomitant breakthrough-bleed treatment.
How serious is the interaction between Concizumab and Factor viii?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Treat breakthrough bleeds with the lowest approved factor VIII dose that achieves hemostasis. Monitor for signs of thrombosis.
What other medicines interact with Concizumab?
MediHelp also lists interactions of Concizumab with, for example, Factor ix. The full list is on the Concizumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
